These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
593 related articles for article (PubMed ID: 23002969)
21. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Dagan R Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365 [TBL] [Abstract][Full Text] [Related]
22. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191 [TBL] [Abstract][Full Text] [Related]
23. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Link-Gelles R; Taylor T; Moore MR; Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813 [TBL] [Abstract][Full Text] [Related]
24. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Wiertsema SP; Kirkham LA; Corscadden KJ; Mowe EN; Bowman JM; Jacoby P; Francis R; Vijayasekaran S; Coates HL; Riley TV; Richmond P Vaccine; 2011 Jul; 29(32):5163-70. PubMed ID: 21621576 [TBL] [Abstract][Full Text] [Related]
25. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773 [TBL] [Abstract][Full Text] [Related]
26. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. Muñoz-Almagro C; Ciruela P; Esteva C; Marco F; Navarro M; Bartolome R; Sauca G; Gallés C; Morta M; Ballester F; Raga X; Selva L; J Infect; 2011 Aug; 63(2):151-62. PubMed ID: 21679725 [TBL] [Abstract][Full Text] [Related]
27. Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era. Kendall BA; Dascomb KK; Mehta RR; Mason EO; Ampofo K; Pombo DJ; Pavia AT; Byington CL Vaccine; 2011 Nov; 29(49):9123-6. PubMed ID: 22001280 [TBL] [Abstract][Full Text] [Related]
28. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458 [TBL] [Abstract][Full Text] [Related]
29. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ; Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105 [TBL] [Abstract][Full Text] [Related]
30. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. Harboe ZB; Valentiner-Branth P; Ingels H; Rasmussen JN; Andersen PH; Bjerre CC; Goldblatt D; Ashton L; Haston M; Konradsen HB; Lambertsen L; PLoS One; 2013; 8(1):e51460. PubMed ID: 23365635 [TBL] [Abstract][Full Text] [Related]
31. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542 [TBL] [Abstract][Full Text] [Related]
33. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Zangeneh TT; Baracco G; Al-Tawfiq JA Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802 [TBL] [Abstract][Full Text] [Related]
34. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. Madhi SA; Cohen C; von Gottberg A Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016 [TBL] [Abstract][Full Text] [Related]
35. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Dagan R; Givon-Lavi N; Porat N; Greenberg D Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519 [TBL] [Abstract][Full Text] [Related]
36. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Cohen R; Levy C; Bingen E; Koskas M; Nave I; Varon E Pediatr Infect Dis J; 2012 Mar; 31(3):297-301. PubMed ID: 22330166 [TBL] [Abstract][Full Text] [Related]
38. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920 [TBL] [Abstract][Full Text] [Related]
39. Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine. Durando P; Alicino C; De Florentiis D; Martini M; Icardi G J Prev Med Hyg; 2012 Jun; 53(2):68-77. PubMed ID: 23240163 [TBL] [Abstract][Full Text] [Related]
40. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom. Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]